Radiotherapy company CIVCO Radiotherapy revealed on Monday the receipt of US FDA 510k clearance and EU CE mark for the Solstice SRS Immobilization System with variable pitch capability and positioning flexibility in aid of patients and doctors in radiotherapy clinics.
The company added that the Solstice SRS Immobilization System will be launched in the market following its display at the American Society for Radiation Oncology (ASTRO) Meeting from 21-24 October 2018 in San Antonio, Texas.
According to the company, the Solstice SRS Immobilization System creates a highly customisable and comfortable head and neck immobilisation system for precise treatment to improve patient outcomes. The system is comprised of a carbon fibre head support, customisable cushion and dedicated thermoplastic mask designed for secure and simple attachment.
In addition, the company's patient-centric solutions include advanced patient immobilisation and positioning hardware and consumables, fiducial markers, couchtops and overlays, software, patient care products and advanced 6DOF robotic patient positioning.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval